Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.
Elisa Krill-Jackson, MD
Advertisement
Articles by Elisa Krill-Jackson, MD
Elisa Krill-Jackson, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in the treatment of patients with metastatic breast cancer.
Advertisement
Latest Updated Articles
- Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Published: March 12th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5